Table 1.
Characteristics of the 487 patients included and their outcome charts.
| Characteristic | Average ± SD (%) |
|---|---|
| Demographic and clinical data | |
| Age | 47.47 ± 19.68 |
| Gender | |
| Male | 292 (60.0) |
| Female | 195 (40.0) |
| Fever | 220 (45.1) |
| Abdominal pain | 253 (52.2) |
| Leucocytes, k/ml | 15.11 ± 12.14 |
| Albumin | 2.17 ± 0.71 |
| Creatinine | 2.10 ± 3.16 |
| Bowel movements per daya | |
| ≤3 | 84 (26.4) |
| 4–6 | 158 (49.7) |
| ≥7 | 76 (23.9) |
| ATLAS score | 4.91 + 1.71 |
| 0–3 points | 41 (18.7) |
| 4–7 points | 160 (73.4) |
| 8–10 points | 17 (7.8) |
| Primary diagnosis | |
| Medical | 70.0% |
| Surgical | 30.0% |
| Comorbidities and predisposing risk factors | |
| Total LOS LOS before diagnosis LOS after diagnosis |
20.19 ± 21.37 13.66 ± 14.96 15.25 ± 15.65 |
| Previous ICU stay | 68 (13.9) |
| Immunosuppression | |
| Invasive mechanical ventilation | 40 (8.2) |
| Proton pump inhibitors | 373 (76.5) |
| H2 blockers | 40 (8.2) |
| Diagnosis of CDI | |
| Immunoassay for toxins A/B | 192 (39.4) |
| PCR | 284 (58.3) |
| C. difficile ribotype 027 | 145/284 (51.1) |
| C. difficile non-027 ribotype | 139/284 (48.9) |
| Endoscopy (pseudomembranous colitis) | 43 (8.8) |
| Initial treatment of CDI | |
| Metronidazole | 77 (35.3) |
| Vancomycin | 34 (15.7) |
| Vancomycin + Metronidazole | 105 (48.2%) |
| Fecal microbiota transplant | 8 (3.7%) |
| Rifaximin | 1 (0.5) |
| Colectomy | 1 (0.5) |
| Treatment duration (days) | 9.76 ± 4.74 |
| Treatment failurea | 42/218 (19.3) |
| 30-day mortality | 88 (18.1) |
| Attributable mortality | 44 (9.0) |
a
Clinical information was not available for all of the patients.